Immunology and Microbiology
Arm
20%
CD4 Lymphocyte Count
20%
Coinfection
20%
Decision Making
20%
Glomerulus Filtration
80%
Hepatitis C
20%
High Risk Population
20%
Human Immunodeficiency Virus
100%
Human Immunodeficiency Virus Infection
100%
Low Risk Population
20%
Tenofovir
40%
Nursing and Health Professions
Adverse Event
6%
Atazanavir
6%
Atazanavir Plus Ritonavir
20%
Cardiovascular Disease
6%
CD4 Lymphocyte Count
6%
Chronic Kidney Failure
100%
Clinical Practice
6%
Drug Use
6%
Estimated Glomerular Filtration Rate
26%
Hepatitis C
6%
High Risk Population
6%
Hospital
6%
Human Immunodeficiency Virus
33%
Human Immunodeficiency Virus Infection
100%
Lopinavir Plus Ritonavir
20%
Low Risk Population
6%
Mixed Infection
6%
Number Needed to Harm
20%
Proteinase Inhibitor
13%
Proteinuria
6%
Rate Ratio
6%
Tenofovir
13%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
6%
Anti-Human Immunodeficiency Virus
6%
Atazanavir
6%
Atazanavir Plus Ritonavir
20%
Cardiovascular Disease
6%
Chronic Kidney Failure
100%
Hepatitis C
6%
HIV
26%
Human Immunodeficiency Virus Infection
100%
Lopinavir Plus Ritonavir
20%
Mixed Infection
6%
Number Needed to Harm
20%
Proteinase Inhibitor
13%
Proteinuria
6%
Tenofovir
13%
Mathematics
Categorical Variable
33%
Incidence Rate
33%
Interquartile Range
33%
Median
100%
Poisson Regression
33%
Rate Value
33%